BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 37550503)

  • 41. A Single Institution's Experience with Cytogenetic and MRD Outcomes in Pediatric Acute Lymphoblastic Leukemia.
    Amjad A; Wali RM; Anjum S; Mansoor R
    J Coll Physicians Surg Pak; 2019 Jun; 29(6):549-552. PubMed ID: 31133155
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Comparison of minimal residual disease (MRD) monitoring by WT1 quantification between childhood acute myeloid leukemia and acute lymphoblastic leukemia.
    Zhang R; Yang JY; Sun HQ; Jia H; Liao J; Shi YJ; Li G
    Eur Rev Med Pharmacol Sci; 2015; 19(14):2679-88. PubMed ID: 26221900
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study.
    Conter V; Bartram CR; Valsecchi MG; Schrauder A; Panzer-Grümayer R; Möricke A; Aricò M; Zimmermann M; Mann G; De Rossi G; Stanulla M; Locatelli F; Basso G; Niggli F; Barisone E; Henze G; Ludwig WD; Haas OA; Cazzaniga G; Koehler R; Silvestri D; Bradtke J; Parasole R; Beier R; van Dongen JJ; Biondi A; Schrappe M
    Blood; 2010 Apr; 115(16):3206-14. PubMed ID: 20154213
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Differing Outcomes of Patients with High Hyperdiploidy and ETV6-RUNX1 Rearrangement in Korean Pediatric Precursor B Cell Acute Lymphoblastic Leukemia.
    Lee JW; Kim S; Jang PS; Chung NG; Cho B
    Cancer Res Treat; 2021 Apr; 53(2):567-575. PubMed ID: 33070555
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Clinical study on childhood acute lymphoblastic leukemia diagnosed and treated with 04 Protocol in Chongqing, China].
    Liang XL; Xian Y; Dai BT; Xu YH; Su YC; Wang SY; Lu LL; Li X; Yu J
    Zhonghua Er Ke Za Zhi; 2009 Dec; 47(12):939-41. PubMed ID: 20193149
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The long-term results of childhood acute lymphoblastic leukemia at two centers from Turkey: 15 years of experience with the ALL-BFM 95 protocol.
    Güneş AM; Oren H; Baytan B; Bengoa SY; Evim MS; Gözmen S; Tüfekçi O; Karapınar TH; Irken G
    Ann Hematol; 2014 Oct; 93(10):1677-84. PubMed ID: 24863691
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Effect of Huangqi injection on short-term prognosis in children with acute lymphoblastic leukemia].
    Yan PH; Yan M; Wang XM; Wang SH
    Zhongguo Dang Dai Er Ke Za Zhi; 2014 Feb; 16(2):141-6. PubMed ID: 24568906
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Minimal residual disease is an important predictive factor of outcome in children with relapsed 'high-risk' acute lymphoblastic leukemia.
    Paganin M; Zecca M; Fabbri G; Polato K; Biondi A; Rizzari C; Locatelli F; Basso G
    Leukemia; 2008 Dec; 22(12):2193-200. PubMed ID: 18754029
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Genomics of next generation sequencing in pediatric B-acute lymphoblastic leukemia and its impact on minimal residual disease].
    Gao YY; Jia YJ; Qi BQ; Zhang XY; Chen YM; Zou Y; Guo Y; Yang WY; Zhang L; Wang SC; Zhang RR; Liu TF; Song Z; Zhu XF; Chen XJ
    Zhonghua Er Ke Za Zhi; 2023 Jun; 61(6):527-532. PubMed ID: 37312464
    [No Abstract]   [Full Text] [Related]  

  • 50. Treatment abandonment in childhood acute lymphoblastic leukaemia in China: a retrospective cohort study of the Chinese Children's Cancer Group.
    Cai J; Yu J; Zhu X; Hu S; Zhu Y; Jiang H; Li C; Fang Y; Liang C; Ju X; Tian X; Zhai X; Hao J; Hu Q; Wang N; Jiang H; Sun L; Li CK; Pan K; Yang M; Shen S; Cheng C; Ribeiro RC; Pui CH; Tang J;
    Arch Dis Child; 2019 Jun; 104(6):522-529. PubMed ID: 30705079
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Prognostic role of minimal residual disease in mature B-cell acute lymphoblastic leukemia of childhood.
    Mussolin L; Pillon M; Conter V; Piglione M; Lo Nigro L; Pierani P; Micalizzi C; Buffardi S; Basso G; Zanesco L; Rosolen A
    J Clin Oncol; 2007 Nov; 25(33):5254-61. PubMed ID: 18024872
    [TBL] [Abstract][Full Text] [Related]  

  • 52. ETV6-RUNX1-positive childhood acute lymphoblastic leukemia: improved outcome with contemporary therapy.
    Bhojwani D; Pei D; Sandlund JT; Jeha S; Ribeiro RC; Rubnitz JE; Raimondi SC; Shurtleff S; Onciu M; Cheng C; Coustan-Smith E; Bowman WP; Howard SC; Metzger ML; Inaba H; Leung W; Evans WE; Campana D; Relling MV; Pui CH
    Leukemia; 2012 Feb; 26(2):265-70. PubMed ID: 21869842
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [The Best Time of Minimal Residual Disease Monitoring for Predicting Survival and Prognosis in Children with T-Cell Acute Lymphoblastic Leukemia].
    Bao H; Li TY; Wu YT; Xiao ZT; Zhang L; Luo LY
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2021 Oct; 29(5):1471-1477. PubMed ID: 34627426
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Preliminary results of the use of MRD test among children with acute lymphoblastic leukaemia].
    Raciborska A; Wypych A; Rokicka-Milewska R; Siedlecki JA; Kulik J
    Przegl Lek; 2004; 61 Suppl 2():62-6. PubMed ID: 15686049
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Clinical Significance of Minimal Residual Disease in Pediatric Patients with
    Xue YJ; Lu AD; Wang Y; Jia YP; Zuo YX; Zhang LP
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Oct; 31(5):1303-1308. PubMed ID: 37846676
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Low absolute neutrophil count during induction therapy is an adverse prognostic factor in childhood acute lymphoblastic leukaemia.
    Chen X; Liu C; Zhang A; Wu W; Liu L; Lan Y; Yi M; Zhang L; Ruan M; Chang L; Zhang L; Zou Y; Chen Y; Yang W; Guo Y; Chen X; Zhang Y; Zhu X
    Ann Hematol; 2021 Sep; 100(9):2269-2277. PubMed ID: 33443592
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Persistent MRD before and after allogeneic BMT predicts relapse in children with acute lymphoblastic leukaemia.
    Sutton R; Shaw PJ; Venn NC; Law T; Dissanayake A; Kilo T; Haber M; Norris MD; Fraser C; Alvaro F; Revesz T; Trahair TN; Dalla-Pozza L; Marshall GM; O'Brien TA
    Br J Haematol; 2015 Feb; 168(3):395-404. PubMed ID: 25312094
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood.
    van Dongen JJ; Seriu T; Panzer-Grümayer ER; Biondi A; Pongers-Willemse MJ; Corral L; Stolz F; Schrappe M; Masera G; Kamps WA; Gadner H; van Wering ER; Ludwig WD; Basso G; de Bruijn MA; Cazzaniga G; Hettinger K; van der Does-van den Berg A; Hop WC; Riehm H; Bartram CR
    Lancet; 1998 Nov; 352(9142):1731-8. PubMed ID: 9848348
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Rapid molecular response during early induction chemotherapy predicts a good outcome in childhood acute lymphoblastic leukemia.
    Panzer-Grümayer ER; Schneider M; Panzer S; Fasching K; Gadner H
    Blood; 2000 Feb; 95(3):790-4. PubMed ID: 10648387
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Pre-transplant MRD negativity predicts favorable outcomes of CAR-T therapy followed by haploidentical HSCT for relapsed/refractory acute lymphoblastic leukemia: a multi-center retrospective study.
    Zhao H; Wei J; Wei G; Luo Y; Shi J; Cui Q; Zhao M; Liang A; Zhang Q; Yang J; Li X; Chen J; Song X; Jing H; Li Y; Hao S; Wu W; Tan Y; Yu J; Zhao Y; Lai X; Yin ETS; Wei Y; Li P; Huang J; Wang T; Blaise D; Xiao L; Chang AH; Nagler A; Mohty M; Huang H; Hu Y
    J Hematol Oncol; 2020 May; 13(1):42. PubMed ID: 32366260
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.